Children with idiopathic generalized epilepsy those underwent at least two years seizure remission: a retrospective analysis

Chandan Raybarman

doi:10.18203/2349-3291.ijcp20213311

Authors

Chandan Raybarman Department of Pediatrics, Gauri Devi Institute of Medical Sciences and Hospital, Durgapur, West Bengal, India http://orcid.org/0000-0001-8368-6308

DOI:

https://doi.org/10.18203/2349-3291.ijcp20213311

Keywords:

Idiopathic generalized epilepsy, Index antiepileptic drugs, Very early add on, 2 years seizure remission, Initial target doses

Abstract

Background: The aim of the retrospective study was to evaluate the effectiveness of the index antiepileptic drugs in children with idiopathic generalized epilepsy who underwent at least 2 years remission.

Methods: A total of 52 children with idiopathic generalized epilepsy who underwent at least 2 years remission were identified retrospectively from the records of the paediatric and neurology care clinic from April 2017 to December 2020.

Results: The seizure patterns of 52 cases were tonic-clonic seizures alone (73%), a combination of tonic-clonic seizures and absences (13.5%), and combined tonic-clonic seizures and myoclonus (13.5%). The total number of seizures at enrolment in all (age at seizure onset 7.44±5.12 years, male-female ratio (31:21) was 651 (mean 12.52±26.60). The total number of follow-up visits in all was 6.62±14.44 consisting of 1177.5±772.86 days of follow-up periods. All patients continued index antiepileptic drugs with initial target doses varies from low to moderate ranges. Add-on therapy was initiated in 43% of cases around the titration phase of index antiepileptic drugs (i.e. very early add-on). Treatment trends reveal increased use of 1st generation antiepileptic drugs than 2nd and 3rd generation. 2 years seizure remission rates were 55.77% by index antiepileptic drugs only therapy and 44.23% by very early add-on therapy. The seizure remission period was mean±SD 858.71±209.08 days.

Conclusions: Index antiepileptic drugs with low to moderate initial target doses lead to achieving 2 years or more seizure remission. Very early add-on therapy is the novelty and leads to achieving the goal.

Metrics

Metrics Loading ...

References

Camfield P, Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord. 2015;17(2):117-23.

Berg AT, Levy SR, Testa FM, Shinnar S. Classification of childhood epilepsy syndromes in newly diagnosed epilepsy: interrater agreement and reasons for disagreement. Epilepsia. 1999;40(4):439-44.

Wirrell EC, Grossardt BR, Kisiel LC, Nickels KC. Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: a population-based study. Epilepsy Res. 2011;95(1):110-8.

Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512-21.

Cavanna AE. Behavioural neurology of antiepileptic drugs: a practical guide. 1st ed. Oxford University Press; 2018.

Yılmaz U, Yılmaz TS, Dizdarer G, Akıncı G, Guzel O, Tekgul H. Efficacy and tolerability of the first antiepileptic drug in children with newly diagnosed idiopathic epilepsy. Seizure. 2014;23(4):252-9.

Meyer AC, Dua T, Ma J, Saxena S, Birbeck G. Global disparities in the epilepsy treatment gap: a systematic review. Bull World Health Organ. 2010;88(4):260-6.

Sillanpaa M, Schmidt D, Saarinen MM, Shinnar S. Remission in epilepsy: How long is enough? Epilepsia. 2017;58(5):901-6.

Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-82.

Berg AT, Shinnar S, Levy SR, Testa FM, Rapaport S, Beckerman B, et al. Two-year remission and subsequent relapse in children with newly diagnosed epilepsy. Epilepsia. 2001;42(12):1553-62.

Poolos NP, Castagna CE, Williams S, Miller AB, Story TJ. Association between antiepileptic drug dose and long-term response in patients with refractory epilepsy. Epilepsy Behav. 2017;69:59-68.

Chen Z, Brodie MJ, Liew D, Kwan P. Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study. JAMA Neurol. 2018;75(3):279-86.

Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia. 2001;42(10):1255-60.

Fishman J, Kalilani L, Song Y, Swallow E, Wild I. Antiepileptic Drug Titration and Related Health Care Resource Use and Costs. J Manag Care Spec Pharm. 2018;24(9):929-38.

Powell G, Logan J, Kiri V, Borghs S. Trends in antiepileptic drug treatment and effectiveness in clinical practice in England from 2003 to 2016: a retrospective cohort study using electronic medical records. BMJ Open. 2019;9(12):32551.

Radhakrishnan A. Bridging the treatment gap in epilepsy-is there an emerging trend in the use of newer antiepileptic drugs? Neurol India. 2016;64(6):1140-2.

Hempelmann A, Taylor KP, Heils A, Lorenz S, Prud'homme JF, Nabbout R, et al. Exploration of the genetic architecture of idiopathic generalized epilepsies. Epilepsia. 2006;47(10):1682-90.

Marini C, Scheffer IE, Crossland KM, Grinton BE, Phillips FL, Mahon JM, et al. Genetic architecture of idiopathic generalized epilepsy: clinical genetic analysis of 55 multiplex families. Epilepsia. 2004;45(5):467-78.

Callenbach PM, Geerts AT, Arts WF, Donselaar CA, Peters AC, Stroink H, Brouwer OF. Familial occurrence of epilepsy in children with newly diagnosed multiple seizures: Dutch Study of Epilepsy in Childhood. Epilepsia. 1998;39(3):331-6.

Vorderwülbecke BJ, Kowski AB, Kirschbaum A, Merkle H, Senf P, Janz D, et al. Long-term outcome in adolescent-onset generalized genetic epilepsies. Epilepsia. 2017;58(7):1244-50.

Sinha S, Pramod MN, Dilipkumar S, Satishchandra P. Idiopathic generalized epilepsy: Phenotypic and electroencephalographic observations in a large cohort from South India. Ann Indian Acad Neurol. 2013;16(2):163-8.

Leung AK, Hon KL, Leung TN. Febrile seizures: an overview. Drugs Context. 2018;7:212536.

Myers KA, Scheffer IE, Berkovic SF, ILAE Genetics Commission. Genetic literacy series: genetic epilepsy with febrile seizures plus. Epileptic Disord. 2018;20(4):232-8.

Elmali AD, Auvin S, Bast T, Rubboli G, Koutroumanidis M. How to diagnose and classify idiopathic (genetic) generalized epilepsies. Epileptic Disord. 2020;22(4):399-420.

Bernasconi A, Cendes F, Theodore WH, Gill RS, Koepp MJ, Hogan RE, et al. Recommendations for the use of structural magnetic resonance imaging in the care of patients with epilepsy: A consensus report from the International League Against Epilepsy Neuroimaging Task Force. Epilepsia. 2019;60(6):1054-68.

Benbadis SR, Beniczky S, Bertram E, Maciver S, Moshé SL. The role of EEG in patients with suspected epilepsy. Epileptic Disord. 2020;22(2):143-55.